^
    17d
    COrticosteroids for Biphasic Reactions in Anaphylaxis - COBRA (ACTRN12624001339549)
    P3, N=250, Not yet recruiting, Te Whatu Ora Waikato
    New P3 trial
    |
    prednisone • prednisolone
    19d
    IA-GRACE-IgANT: Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate At Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy? (clinicaltrials.gov)
    P4, N=585, Not yet recruiting, Christian Medical College, Vellore, India
    New P4 trial • Biopsy
    |
    hydroxychloroquine • prednisolone
    25d
    MORAb-202-G000-201: A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types (clinicaltrials.gov)
    P1/2, N=142, Recruiting, Eisai Inc. | Trial completion date: Mar 2025 --> Oct 2024 | Trial primary completion date: Mar 2025 --> Oct 2024
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • ER (Estrogen receptor) • ALK (Anaplastic lymphoma kinase) • PGR (Progesterone receptor) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    HER-2 negative • PGR negative
    |
    prednisone • dexamethasone • farletuzumab ecteribulin (MORAb-202) • prednisolone
    27d
    Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas (clinicaltrials.gov)
    P1/2, N=18, Completed, University of Colorado, Denver | Active, not recruiting --> Completed
    Trial completion
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK positive • ALK negative
    |
    Opdivo (nivolumab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisolone
    1m
    Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (clinicaltrials.gov)
    P2, N=171, Not yet recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2027 --> Dec 2028 | Initiation date: Oct 2024 --> Jan 2025 | Trial primary completion date: Dec 2027 --> Dec 2028
    Trial completion date • Trial initiation date • Trial primary completion date • Combination therapy
    |
    MCL1 (Myeloid cell leukemia 1) • KMT2A (Lysine Methyltransferase 2A) • BCL2L1 (BCL2-like 1)
    |
    BCL2 expression
    |
    Venclexta (venetoclax) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • prednisolone
    2ms
    Low remission rates and high incidence of adverse events in a prospective VEXAS syndrome registry. (PubMed, Rheumatology (Oxford))
    Patients with VEXAS syndrome required high-dose glucocorticoids to achieve remission, and complications-such as malignancy, thrombosis, and infection-occurred frequently within a short observation period.
    Journal • Adverse events
    |
    CRP (C-reactive protein)
    |
    prednisolone
    2ms
    waveLINE-007: A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007) (clinicaltrials.gov)
    P2, N=60, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting | Trial completion date: Jan 2026 --> Apr 2029 | Trial primary completion date: Jan 2026 --> Apr 2029
    Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • prednisone • Truxima (rituximab-abbs) • zilovertamab vedotin (MK-2140) • prednisolone
    2ms
    Treatment Effects of Chinese Medicine (Yi-Qi-Qing-Jie Herbal Compound) Combined With Immunosuppression Therapies in IgA Nephropathy Patients With High-risk of ESRD (clinicaltrials.gov)
    P2/3, N=60, Active, not recruiting, Guang'anmen Hospital of China Academy of Chinese Medical Sciences | Trial primary completion date: Dec 2023 --> Sep 2024
    Trial primary completion date
    |
    cyclophosphamide • prednisolone
    3ms
    Using the Blood Eosinophil Count to Guide Systemic Corticosteroid Treatment in Asthma Exacerbations (clinicaltrials.gov)
    P2, N=110, Active, not recruiting, Changi General Hospital | Recruiting --> Active, not recruiting
    Enrollment closed • Head-to-Head
    |
    prednisolone
    4ms
    Bilateral Hemorrhagic Occlusive Retinal Vasculitis Induced by Osimertinib in a Patient with Non-Small Cell Lung Cancer. (PubMed, Ocul Immunol Inflamm)
    Eighteen months before symptom onset, the treatment was changed from afatinib (20 mg/day) to osimertinib (80 mg/day) because of tumor progression...Osimertinib was reduced to 40 mg/day, and oral prednisolone was started at 30 mg/day...Osimertinib, a third-generation tyrosine kinase inhibitor, can be used to treat advanced non-small cell lung cancer with epidermal growth factor receptor mutation-induced bilateral HORV. This adverse effect can be managed with systemic and local steroid treatment and continued osimertinib administration.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    Tagrisso (osimertinib) • Gilotrif (afatinib) • prednisolone
    4ms
    Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP (clinicaltrials.gov)
    P=N/A, N=0, Withdrawn, Australasian Leukaemia and Lymphoma Group | N=130 --> 0 | Unknown status --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • ondansetron • prednisolone
    4ms
    Simultaneous distinct cutaneous fungal infections with chromoblastomycosis due to Exophiala xenobiotica and hyalohyphomycosis due to Scedosporium apiospermum in a patient with severe cellular immunodeficiency. (PubMed, J Dermatol)
    A 92-year-old Japanese man who had been taking oral prednisolone for an IgG4-related respiratory disease visited our clinic...IFN-γ producing type 1 T helper (Th1) cells play an important role in the defense against fungal infections, however, corticosteroids specifically suppress Th1 cell responses and promote the induction of fungal infection. Measurement of PHA-stimulated LTT and serum IFN-γ may be useful in determining the severity and prognosis of deep-seated dermatomycosis in patients undergoing corticosteroid treatment.
    Journal
    |
    IFNG (Interferon, gamma)
    |
    prednisolone
    5ms
    A Phase Ⅱa Study of the Safety, Tolerability and Efficacy of BD111 in Herpes Simplex Virus Type I Stromal Keratitis (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, Shanghai BDgene Co., Ltd.
    New P2 trial • Stroma
    |
    prednisolone
    5ms
    A Study of the Safety, Tolerability and Prelinminary Efficacy of BD111 in Herpes Simplex Virus Type I Stromal Keratitis (clinicaltrials.gov)
    P1, N=16, Recruiting, Shanghai BDgene Co., Ltd.
    New P1 trial • Stroma
    |
    prednisolone • valacyclovir
    5ms
    Efficacy and Safety of Hydroxychloroquine in the Treatment of Sudden Sensorineural Hearing Loss (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, Chang Gung Memorial Hospital
    New P2 trial
    |
    hydroxychloroquine • prednisolone
    6ms
    Transient Bacillary Layer Detachment During the Disease Course of Primary Vitreoretinal Lymphoma. (PubMed, Ocul Immunol Inflamm)
    A 50 year-old woman was referred to us with a 2-month history of vitritis in both eyes, poorly responding to oral prednisolone...During the disease course, optical coherence tomography of the macula showed a BALAD in the right eye, which resolved during follow-up. Our case indicates that BALAD is a possible rare manifestation of PVRL, and this should be considered in the differential diagnosis process in order to avoid diagnostic delays.
    Journal
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor)
    |
    prednisolone
    6ms
    The STOP Study: Silicosis Treatment Of Prednisolone (ACTRN12623000622606)
    P2, N=10, Recruiting, Alfred Health | Not yet recruiting --> Recruiting
    Enrollment open • Trial initiation date
    |
    CRP (C-reactive protein)
    |
    prednisolone
    6ms
    Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (clinicaltrials.gov)
    P3, N=244, Recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2028 --> Sep 2027 | Trial primary completion date: Dec 2028 --> Sep 2027
    Trial completion date • Trial primary completion date • Combination therapy
    |
    Opdivo (nivolumab) • Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • Truxima (rituximab-abbs) • Rituxan Hycela (rituximab/hyaluronidase) • Neulasta (pegfilgrastim) • ABP 206 (nivolumab biosimilar) • Mabtas (rituximab biosimilar) • Neupogen (filgrastim) • prednisolone
    6ms
    PREMI: Prednisolone Administration in Patients With Unexplained REcurrent MIscarriages (clinicaltrials.gov)
    P4, N=490, Recruiting, Leiden University Medical Center | Phase classification: P2 --> P4
    Phase classification
    |
    CD163 (CD163 Molecule) • CD14 (CD14 Molecule)
    |
    prednisolone
    6ms
    Successful Treatment with Mycophenolate Mofetil in a Patieint with Anti-MDA 5 Antibody-positive Interstitial Lung Disease and Posterior Reversible Encephalopathy syndrome: A Case Report. (PubMed, Intern Med)
    However, the patient reported a severe headache following treatment with oral prednisolone and tacrolimus. Tacrolimus was discontinued, and mycophenolate mofetil was instead administered with a favorable outcome. Mycophenolate mofetil should therefore be considered as an alternative treatment for anti-MDA-5-positive interstitial lung disease in cases where calcineurin inhibitors cannot be used.
    Journal
    |
    IFIH1 (Interferon Induced With Helicase C Domain 1)
    |
    prednisolone
    7ms
    RATHL: Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma (clinicaltrials.gov)
    P3, N=1202, Completed, University College, London | Active, not recruiting --> Completed | Trial completion date: May 2023 --> May 2024
    Trial completion • Trial completion date • FDG PET • Metastases
    |
    doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • dacarbazine • Matulane (procarbazine hydrochloride) • bleomycin • vinblastine • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • prednisolone
    7ms
    Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (clinicaltrials.gov)
    P2, N=171, Not yet recruiting, National Cancer Institute (NCI) | Initiation date: Apr 2024 --> Jul 2024
    Trial initiation date • Combination therapy
    |
    MCL1 (Myeloid cell leukemia 1) • KMT2A (Lysine Methyltransferase 2A) • BCL2L1 (BCL2-like 1)
    |
    BCL2 expression
    |
    Venclexta (venetoclax) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • prednisolone
    8ms
    Clinical Study of Rituximab Combined With Corticosteroids or Rituximab Monotherapy in the Treatment of Primary Membranous Nephropathy (clinicaltrials.gov)
    P4, N=78, Recruiting, First Affiliated Hospital, Sun Yat-Sen University | Not yet recruiting --> Recruiting | Trial completion date: Aug 2025 --> Dec 2026 | Trial primary completion date: Aug 2025 --> Sep 2026
    Enrollment open • Trial completion date • Trial primary completion date
    |
    Rituxan (rituximab) • prednisolone
    8ms
    Facial cutaneous Rosai-Dorfman disease: a case report. (PubMed, J Med Case Rep)
    Although cutaneous Rosai-Dorfman disease is considered benign and well medical responded disease, patients with atypical presentation and rapid growing lesion may necessitate aggressive multimodal treatment.
    Journal
    |
    CD68 (CD68 Molecule)
    |
    prednisolone
    8ms
    Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (clinicaltrials.gov)
    P2, N=171, Not yet recruiting, National Cancer Institute (NCI)
    New P2 trial • Combination therapy
    |
    MCL1 (Myeloid cell leukemia 1) • KMT2A (Lysine Methyltransferase 2A) • BCL2L1 (BCL2-like 1)
    |
    BCL2 expression
    |
    Venclexta (venetoclax) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • prednisolone
    9ms
    PREDMETH: Effectiveness of Methotrexate Versus Prednisolone as First-line Therapy for Pulmonary Sarcoidosis (clinicaltrials.gov)
    P4, N=138, Active, not recruiting, Erasmus Medical Center | Recruiting --> Active, not recruiting | Trial completion date: Jan 2025 --> Jul 2026 | Trial primary completion date: Jun 2023 --> Jul 2024
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    methotrexate • prednisolone
    9ms
    The Effect of Three Different Medications on Anesthetic Success and Postoperative Pain (clinicaltrials.gov)
    P=N/A, N=120, Not yet recruiting, Cairo University
    New trial
    |
    prednisolone
    9ms
    Top-down Infliximab Study in Kids With Crohn's Disease (clinicaltrials.gov)
    P4, N=100, Completed, Erasmus Medical Center | Active, not recruiting --> Completed
    Trial completion
    |
    prednisolone
    9ms
    Tolerance: A 3 Arm Randomized Study on Health-related QoL of Elderly Patients With Advanced Soft Tissue Sarcoma (clinicaltrials.gov)
    P3, N=14, Terminated, European Organisation for Research and Treatment of Cancer - EORTC | N=185 --> 14 | Trial completion date: Mar 2027 --> Nov 2023 | Recruiting --> Terminated | Trial primary completion date: Jun 2025 --> Sep 2023; Withdrawal grant provider
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • HEOR • Metastases
    |
    doxorubicin hydrochloride • cyclophosphamide • prednisone • prednisolone
    9ms
    ADAPTinMCN: Active Vitamin D And Reduced Dose Prednisolone for Treatment in Minimal Change Nephropathy (clinicaltrials.gov)
    P4, N=71, Active, not recruiting, University of Aarhus | Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> May 2025 | Trial primary completion date: Dec 2024 --> Feb 2024
    Enrollment closed • Trial completion date • Trial primary completion date • Head-to-Head
    |
    prednisone • prednisolone
    9ms
    GLITZ: Oral Itraconazole Versus Combination of Systemic Glucorticoids and Oral Itraconazole in CPA-ABPA Overlap Syndrome (clinicaltrials.gov)
    P=N/A, N=104, Recruiting, Postgraduate Institute of Medical Education and Research | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial primary completion date
    |
    prednisone • itraconazole • prednisolone
    10ms
    PREMI: Prednisolone Administration in Patients With Unexplained REcurrent MIscarriages (clinicaltrials.gov)
    P2, N=490, Recruiting, Leiden University Medical Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD163 (CD163 Molecule) • CD14 (CD14 Molecule)
    |
    prednisolone
    10ms
    Acute Exacerbations Treated With BenRAlizumab (The ABRA Study) (clinicaltrials.gov)
    P2, N=158, Active, not recruiting, University of Oxford | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    prednisolone
    11ms
    SELECT-TAK: A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK) (clinicaltrials.gov)
    P3, N=56, Active, not recruiting, AbbVie | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    prednisolone
    11ms
    PICA: A Randomized Trial of Prednisolone, Itraconazole, or Their Combination in Allergic Bronchopulmonary Aspergillosis (clinicaltrials.gov)
    P3, N=300, Recruiting, Postgraduate Institute of Medical Education and Research
    New P3 trial
    |
    prednisolone
    12ms
    PREMI: Prednisolone Administration in Patients With Unexplained REcurrent MIscarriages (clinicaltrials.gov)
    P2, N=490, Not yet recruiting, Leiden University Medical Center | Initiation date: Oct 2023 --> Jan 2024
    Trial initiation date
    |
    CD163 (CD163 Molecule) • CD14 (CD14 Molecule)
    |
    prednisolone
    12ms
    CHRONOS-4: Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) (clinicaltrials.gov)
    P3, N=547, Terminated, Bayer | The addition of copanlisib to standard immunochemo therapy did not improve progression-free survival compared to the control arm. Base on the study results, company decided to terminate the study.
    Trial completion date • Trial termination • Combination therapy
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Aliqopa (copanlisib) • vincristine • prednisone • bendamustine • prednisolone
    12ms
    High-TeC: Nasal High-Flow in COPD (clinicaltrials.gov)
    P=N/A, N=136, Recruiting, Marieke Duiverman | Trial completion date: Jul 2023 --> Dec 2025 | Trial primary completion date: May 2023 --> Oct 2025
    Trial completion date • Trial primary completion date
    |
    prednisolone
    1year
    SELECT-TAK: A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK) (clinicaltrials.gov)
    P3, N=56, Recruiting, AbbVie | Trial primary completion date: Aug 2027 --> Apr 2024
    Trial primary completion date
    |
    prednisolone
    1year
    MORAb-202-G000-201: A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types (clinicaltrials.gov)
    P1/2, N=142, Recruiting, Eisai Inc. | N=66 --> 142
    Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • ER (Estrogen receptor) • ALK (Anaplastic lymphoma kinase) • PGR (Progesterone receptor) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • FOLR1 ( Folate receptor alpha )
    |
    HER-2 negative • PGR negative
    |
    prednisone • dexamethasone • farletuzumab ecteribulin (MORAb-202) • prednisolone
    1year
    SELECT-TAK: A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK) (clinicaltrials.gov)
    P3, N=56, Recruiting, AbbVie | Trial primary completion date: Apr 2024 --> Aug 2027
    Trial primary completion date
    |
    prednisolone